Experience with cyproterone acetate in the treatment of precocious puberty.
The authors review their experience (1967-present) in the use of cyproterone acetate (CPA) in precocious puberty. CPA was found effective in persistently suppressing pituitary gonadotropic secretion when administered orally at a dose of 50 mg b.i.d. (70-100 mg/d). After the introduction of gonadotropic analogues (GnRHa) for treatment of central precocious puberty, short term use of CPA was found useful to counteract the initial stimulatory effect of the GnRHa as well as an adjunct drug in case of very active adrenarche causing advanced bone age during GnRHa treatment. The final heights of girls treated with CPA and girls treated with D-Trp6-LHRH were found comparable: 157.8+/-5.1 cm vs 159.6+/-6.3 cm, respectively. The main adverse effects were occasional fatigue due to partial adrenal insufficiency with CPA and gynecomastia in a few boys. Liver function tests were normal in all patients with the exception of one boy with severe hypothalamic disease, including precocious puberty, who developed liver cirrhosis 3 years after stopping CPA following 5 years treatment. Other indications for CPA treatment during childhood and adolescence, such as fast puberty, congenital adrenal hyperplasia and acne, are also mentioned.
Laron
Z
Z
Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, Petah Tikva and Tel Aviv University, Israel.
Kauli
R
R
D001827:Body Height / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury; D017373:Cyproterone Acetate / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006177:Gynecomastia / Q000139:chemically induced; D006801:Humans; D011629:Puberty, Precocious / Q000188:drug therapy*; D012894:Sleep Stages
D017373:Cyproterone Acetate